Abstract
Background: In this study we aimed to discuss whether thegonadal suppression is effective or not in preventing the gonadal toxiceffects of some chemotherapeutics.Methods: Forty Sprague-Dawley adult male rats were randomised into4 groups, each consisting of 10. No drugs were given to the first group. Thesecond group received GnRH agonist and antiandrogen, the third groupreceived COPP chemotherapy protocol and the last group received COPPtogether with GnRH agonist and antiandrogen. Ninety days after drugapplication we sacrificed all rats. Total body weight, testicular weight andtesticular size measurements were all recorded. All testicular tissues wereexamined histologically for the ratio of active seminiferous tubules.Results: There was no difference in total body weight. The weight andmeasurements of testicular tissues were decreased in-group 3 and 4 whencompared with 1 and 2. The amount of active seminiferous tubules wassignificantly less in the third group.Conclusions: As a conclusion we think that gonadal suppressionapplied during chemotherapy regimen could decrease the testicular toxiceffects of chemotherapeutic but more clinical investigations needed forroutine application.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cespedes RD, Samuel J, Jackson C. Protective of germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a LHRH agonist and antiandrogen therapy. Urology 1995; 46(5): 688–691.
Delic JI, Busch C, Peckham MJ. Protection from procarbazine induced testicular damage of spermatogenesis in the rat by androgen. Cancer Res, 1986; 46: 1909–1914.
Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide induced testicular damage with an analogue of GnRH. Lancet 1981; 1: 1132–1134.
Johnson DH, Linda R, Hainsworth JD. Effect of LHRH agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985; 65: 832–836.
Krause W, Pfluger KH. Treatment with the GnRH agonist Buserelin to protecy spermatogenesis against cytotoxic treatment in young men. Andrologia 1989; 21: 265–270.
Kuber W, Treu T, Kratzik C et al. Chemical castration using a depot LH–RH agonist as a palliative therapy concept in prostatic carcinoma clinical, endocrinological and experimental studies. Wien Klin Wochenschr 1990; 102: 640–647.
Lewis RW, Dowling KJ, Schally AV. D-Tryptophan-6 analogue of LHRH-releasing hormone as a protective agent againts testicular damage caused by cyclophosphamide babons. Proc Natl Acad Sci 1985; 82: 2975–2979.
Nonomuro M, Okada K, Hida S. Does a GnRH analogue prevent cisplatin-induced spermatogenetic impairment. Urol Res 1991; 19: 135–140.
Sasagawa I, Nagawa T. Hormonal pattern and testicular histology after treatment with different doses of GnRH analogue in patients with prostate cancer. Int J Fertil 1993; 38: 338–342.
Ward JA, Robinson J, Furr BJ et al. Protection of spermatogenesis in the rats from the cytotoxic procarbazine by the depot of formulation of Zoladex, a GnRH agonist. Cancer Res 1990; 50(3): 568–574.
Waxman JH, Ahmed R, Smith D et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19: 159–162.
Withers HR, Hunner N, Barkley HT, Reid BO. Radiation survival and regeneration characteristics of spermatogonial stem cells of mouse testis. Radiat Res 1974; 57: 88–103.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Göçmen, M., Akay, A.F., Şahin, H. et al. The effects of GnRH analogues and antiandrogenes in preventing the gonadotoxic effects of COPP chemotherapy. Int Urol Nephrol 33, 651–654 (2001). https://doi.org/10.1023/A:1020518916072
Issue Date:
DOI: https://doi.org/10.1023/A:1020518916072